Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom

References

• National Institute for Health and Care Excellence. Cirrhosis in Over 16s: Assessment and Management. NICE guideline 50. 2016
   Google Scholar
• Nadim MK, Durand F, Kellum JA, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 2016;64:717–35
   Google Scholar
• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2017;61:642–59
   Google Scholar
• Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011;33:739–47
   PubMed Web of Science ®Google Scholar
• Das A, Dhiman RK, Saraswat VA, et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001;16:531–5
   PubMed Web of Science ®Google Scholar
• Amodio P, Del Piccolo F, Pettenò E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001;35:37–45
   PubMed Web of Science ®Google Scholar
• Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885–91,891.e1
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010;138:2332–40
   PubMed Web of Science ®Google Scholar
• Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study, Aliment Pharmacol Ther 2011;34:853–61
   PubMed Web of Science ®Google Scholar
• Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010;51:1675–82
   PubMed Web of Science ®Google Scholar
• Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890–5
   PubMed Web of Science ®Google Scholar
• Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease, Liver Transpl 2007;13:1366–71
   PubMed Web of Science ®Google Scholar
• World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, 2nd edn. Geneva: World Health Organization; 2004
   Google Scholar
• Health Protection Agency, NHS Liver Care. NHS Atlas of Variation in Healthcare for People with Liver Disease. 2013
   Google Scholar
• Patidar KR, Thacker LR, Wade JB, et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014;109:1757–63
   PubMed Web of Science ®Google Scholar
• Orr JG, Currie CJ, Berni E, et al. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-alpha. Liver In 2016;36:1295–303
   PubMed Web of Science ®Google Scholar
• Bannister CA, Orr JG, Reynolds AV, et al. Natural history of patients taking rifaximin-alpha for recurrent hepatic encephalopathy and risk of future overt episodes and mortality: a post-hoc analysis of clinical trials data. Clin Ther 2016;38:1081–89.e4
   PubMed Web of Science ®Google Scholar
• Bongaerts G, Severijnen R, Timmerman H. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Med Hypotheses 2005;64:64–8
   PubMed Web of Science ®Google Scholar
• Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071–81
   PubMed Web of Science ®Google Scholar
• Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014;12:1390–7.e2
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Rifaximin for preventing episodes of overt hepatic encephalopathy. NICE technology appraisal guidance 337. 2015
   Google Scholar
• Goel A, Patel N, Blackwell R, et al. PWE-125 Rifaximin Treatment in Hepatic Encephalopathy: Marked Reduction in Hospital Admissions and Hospital Bed Day Occupancy in a District General Hospital in the UK. Gut 2014;63:A179-80.
   Google Scholar
• Valliani T, Sumner M, Gordon F. Rifaximin Treatment in Hepatic Encephalopathy – a Single Centre Experience. Poster presentation at Falk Symposium 186. Challenges of liver cirrhosis and tumors: prevent it, treat it, manage consequences; 2012, October 5–6, Mainz, Germany.
   Google Scholar
• Orr J, Perez F, Mitchison H, et al. PTU-112 Rifaximin for Hepatic Encephalopathy is Cost Effective at Reducing Emergency Hospital Admission. Gut 2013;62:A91-2.
   Google Scholar
• Roach J, Heron T, Henry E, Dillon JF. The Real World Experience of Rifaximin in Hepatic Encephalopathy. Poster presentation at Falk Symposium 191. Liver Diseases in 2013: Advances in Pathogenesis and Treatment; 2013 October 4–5, London, UK
   Google Scholar
• HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. 2013. Available at: https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-governent [Last accessed 7th August 2018]
   Google Scholar
• Office for National Statistics. Interim Life Tables: England and Wales, 2010–2012. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/interimlifetables/previousReleases [Last accessed 13 June 2014]
   Google Scholar
• Norgine Pharmaceuticals Limited (data on file). Meta-analysis of the impact of treatment with rifaximin-α on hospital resources in UK clinical practice DOF-XIFAX-006. 2015
   Google Scholar
• Berni E, Bannister C, Poole CD, et al. PWE-154 the first evaluation of the relationship between the Chronic Liver Disease Questionnaire AND THE EQ-5D index in hepatic encephalopathy patients treated with rifaximin-a. Gut 2014;63:A192 LP-A192
   Web of Science ®Google Scholar
• Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295–300
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. PTU-112 Working papers 172chedp. Centre for Health Economics, University of York, 1999.
   Google Scholar
• Joint Formulary Committee. British National Formulary (online). BMJ Group and Pharmaceutical Press. Available at: http://www.medicinescomplete.com [Last accessed 29 June 2017]
   Google Scholar
• Department of Health. NHS Reference Costs. 2011. Available from: https://www.gov.uk/government/collections/nhs-reference-costs [Last accessed 7th August 2018].
   Google Scholar